Daniel Taylor, an expert in insider trading and an associate professor of accounting at the Wharton School of the University of Pennsylvania, has closely monitored stock trades by executives at companies developing coronavirus vaccines. He told NPR that the close timing between the adoption of Bourla‘s stock plan and the press release looked „very suspicious.“

„It‘s wholly inappropriate for executives at pharmaceutical companies to be implementing or modifying 10b5-1 plans the business day before they announce data or results from drug trials,“ Taylor said.